Health Care

ATAI Life Sciences, a Berlin‑based biopharma, pioneers psychedelic and non‑psychedelic drugs for depression, anxiety, PTSD, holding a $2.73B market cap and fueling hope for breakthrough mental health therapies.

Curis Inc. raises $8.5 M via an at‑market private placement, boosting cash for its oncology drug while sparking dilution concerns and short‑selling pressure.

Explore PHARMAESSENTIA CORP’s rise on the Taiwan Stock Exchange—strategic growth, high PE, and China‑focused healthcare innovation revealed.

Discover how Lantheus Holdings’ merger with Curium US Holdings boosts market reach, executive alignment and future growth in the diagnostics sector.

Adocia SAS pushes biotech frontiers with its BioChaperone platform, creating ultra‑rapid insulin and GLP‑1 combos to tackle diabetes and metabolic disorders.

AGENUS Inc’s biotech stock dips as investors weigh its immuno‑oncology ambitions, market volatility, and future growth prospects.

Praxis Precision Medicines pioneers precision genetic neuroscience, targeting hard‑to‑treat brain disorders and promising breakthrough therapies for patients in the U.S.

Akums Drugs and Pharmaceuticals Limited delivers diverse APIs, OTCs, and CDMO services, driving growth across global markets and investor confidence.

BEONE MEDICINES faces a volatile market, urging pipeline expansion, protein‑degrader tech, and investor clarity to sustain its high‑growth oncology valuation.

LifeMD’s Nasdaq slump: a telehealth company’s challenges, 52‑week lows, and future plans to expand global reach and improve profitability.